Advertisement Interim Report: January - March 2014 - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
More info about

Interim Report: January – March 2014

Period January 1 – March 31, 2014

  • Net sales SEK 79.0m (SEK 67.2m)
  • System revenue SEK 49.5m (SEK 46.1m)
  • EBITDA SEK 15.2m (SEK 12.2m)
  • EBITDA margin 19.2% (18.1%)
  • EBIT 5.3m (SEK 3.2m)
  • Net profit SEK 2.8m (SEK 0.4m)
  • EPS before dilution SEK 0.05 (SEK 0.01)
  • Cash flow from operating activities SEK 14.9m (SEK 20.2m)